Bottom line
PJP vs FHLC: the short answer
PJP (Invesco Pharmaceuticals ETF) and FHLC (Fidelity MSCI Health Care Index ETF) are both etfs.
But FHLC is far broader, holding 337 positions to 33 for PJP, so beyond the top names it adds exposure PJP doesn't have.
FHLC is cheaper at 0.084% vs 0.58% — a difference of $50 a year per $10,000 invested.
Over five years, PJP returned +9.0% a year vs +7.2% for FHLC (reporting dates differ).
Updated Nov 19, 2026
PJP vs FHLC side by side
| PJP | FHLC | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Invesco | Fidelity |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.58% | 0.084% |
| Annual cost per $10k | $58 | $8.4 |
| 10-yr cost on $10k (prospectus) | $726 | $108 |
| Max front load | None | None |
| 12b-1 fee | — | 0% |
| 1-yr return | +27.9% | +2.6% |
| 5-yr return (annualized) | +9.0% | +7.2% |
| 10-yr return (annualized) | +5.1% | +8.8% |
| Best quarter | +18.1% | +16.4% |
| Worst quarter | −14.8% | −13.1% |
| Net assets (fund) | $472.1M | $3.3B |
| Number of holdings | 33 | 337 |
| Portfolio turnover | 36% | 3% |
| Returns as of | Dec 31, 2025 | Nov 30, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PJP | FHLC | Difference |
|---|---|---|---|
| 2024 | +9.7% | +2.6% | +7.1% |
| 2023 | −2.2% | +2.5% | −4.7% |
| 2022 | −2.0% | −5.5% | +3.4% |
| 2021 | +14.5% | +20.4% | −5.9% |
| 2020 | +11.2% | +18.1% | −7.0% |
| 2019 | +4.7% | +21.9% | −17.3% |
| 2018 | −1.7% | +5.5% | −7.2% |
| 2017 | +15.3% | +23.3% | −8.0% |
| 2016 | −19.3% | −3.3% | −15.9% |
| 2015 | +11.1% | +7.0% | +4.0% |
Source: Fund prospectus bar charts
Holdings overlap
10 of PJP's top 25 holdings also appear in FHLC's top 25.
| Holding | PJP | FHLC |
|---|---|---|
| Abbott Laboratories | 5.67% | 2.66% |
| AbbVie Inc. | 5.48% | 6.42% |
| Amgen Inc. | 5.33% | 3.00% |
| Johnson & Johnson | 5.18% | 8.93% |
| Merck & Co., Inc. | 5.06% | 4.66% |
| Eli Lilly and Co. | 5.02% | 13.35% |
| Gilead Sciences, Inc. | 4.53% | 2.34% |
| Pfizer Inc. | 4.50% | 2.06% |
| Regeneron Pharmaceuticals, Inc. | 3.14% | 1.15% |
| Bristol-Myers Squibb Co. | 2.94% | 1.93% |
Source: SEC Form N-PORT
PJP top 10
- Invesco Private Prime Fund — 7.93%
- Abbott Laboratories — 5.67%
- AbbVie Inc. — 5.48%
- Amgen Inc. — 5.33%
- Johnson & Johnson — 5.18%
- Merck & Co., Inc. — 5.06%
- Eli Lilly and Co. — 5.02%
- Corcept Therapeutics Inc. — 4.96%
- Gilead Sciences, Inc. — 4.53%
- Pfizer Inc. — 4.50%
FHLC top 10
- Eli Lilly & Co — 13.35%
- Johnson & Johnson — 8.93%
- AbbVie Inc — 6.42%
- UnitedHealth Group Inc — 5.44%
- Merck & Co Inc — 4.66%
- Thermo Fisher Scientific Inc — 3.09%
- Amgen Inc — 3.00%
- Abbott Laboratories — 2.66%
- Gilead Sciences Inc — 2.34%
- Pfizer Inc — 2.06%
FAQ
What is the difference between PJP and FHLC?
Which is cheaper, PJP or FHLC?
Should I own both PJP and FHLC?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.